Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Total Liabilities (2016 - 2025)

Sonoma Pharmaceuticals has reported Total Liabilities over the past 15 years, most recently at $10.2 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 15.83% year-over-year to $10.2 million; the TTM value through Dec 2025 reached $10.2 million, up 15.83%, while the annual FY2025 figure was $9.3 million, 7.89% up from the prior year.
  • Total Liabilities for Q4 2025 was $10.2 million at Sonoma Pharmaceuticals, up from $10.1 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $10.5 million in Q2 2025 and troughed at $7.9 million in Q4 2023.
  • A 5-year average of $8.9 million and a median of $8.7 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: soared 38.26% in 2021 and later dropped 18.66% in 2023.
  • Year by year, Total Liabilities stood at $8.2 million in 2021, then increased by 2.34% to $8.4 million in 2022, then fell by 5.29% to $7.9 million in 2023, then increased by 11.0% to $8.8 million in 2024, then rose by 15.83% to $10.2 million in 2025.
  • Business Quant data shows Total Liabilities for SNOA at $10.2 million in Q4 2025, $10.1 million in Q3 2025, and $10.5 million in Q2 2025.